Literature DB >> 19935711

Rictor is a novel target of p70 S6 kinase-1.

C Treins1, P H Warne, M A Magnuson, M Pende, J Downward.   

Abstract

The rapamycin-insensitive companion of mammalian target of rapamycin (mTOR) (Rictor) is a key member of mTOR complex-2 (mTORC2), which phosphorylates the AGC kinases Akt/PKB, PKC and SGK1 at a C-terminal hydrophobic motif. We identified several novel sites on Rictor that are phosphorylated, including Thr1135, which is conserved across all vertebrates. Phosphorylation of this site on Rictor is stimulated by amino acids and growth factors through a rapamycin-sensitive signaling cascade. We demonstrate here that Rictor is a direct target of the ribosomal protein S6 kinase-1 (S6K1). Rictor phosphorylation at Thr1135 does not lead to major changes in mTORC2-kinase activity. However, phosphorylation of this site turns over rapidly and mediates 14-3-3 binding to Rictor and mTORC2, providing possibility for altered interactions of the complex. These findings reveal an unexpected signaling input into mTORC2, which is regulated by amino acids, growth factors and rapamycin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19935711     DOI: 10.1038/onc.2009.401

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  78 in total

1.  Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2.

Authors:  Delphine Boulbes; Chien-Hung Chen; Tattym Shaikenov; Nitin K Agarwal; Timothy R Peterson; Terri A Addona; Hasmik Keshishian; Steven A Carr; Mark A Magnuson; David M Sabatini; Dos D Sarbassov
Journal:  Mol Cancer Res       Date:  2010-05-25       Impact factor: 5.852

2.  Multiple cytoskeletal pathways and PI3K signaling mediate CDC-42-induced neuronal protrusion in C. elegans.

Authors:  Jamie K Alan; Eric C Struckhoff; Erik A Lundquist
Journal:  Small GTPases       Date:  2013-10-22

3.  Targeting Rb inactivation in cancers by synthetic lethality.

Authors:  Gabriel M Gordon; Wei Du
Journal:  Am J Cancer Res       Date:  2011-06-30       Impact factor: 6.166

4.  Liver clock protein BMAL1 promotes de novo lipogenesis through insulin-mTORC2-AKT signaling.

Authors:  Deqiang Zhang; Xin Tong; Blake Arthurs; Anirvan Guha; Liangyou Rui; Avani Kamath; Ken Inoki; Lei Yin
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

5.  mTORC2 regulates cardiac response to stress by inhibiting MST1.

Authors:  Sebastiano Sciarretta; Peiyong Zhai; Yasuhiro Maejima; Dominic P Del Re; Narayani Nagarajan; Derek Yee; Tong Liu; Mark A Magnuson; Massimo Volpe; Giacomo Frati; Hong Li; Junichi Sadoshima
Journal:  Cell Rep       Date:  2015-04-02       Impact factor: 9.423

6.  Rictor/mTORC2 pathway in oocytes regulates folliculogenesis, and its inactivation causes premature ovarian failure.

Authors:  Zhenguo Chen; Xiangjin Kang; Liping Wang; Heling Dong; Caixia Wang; Zhi Xiong; Wanlu Zhao; Chunhong Jia; Jun Lin; Wen Zhang; Weiping Yuan; Mei Zhong; Hongzi Du; Xiaochun Bai
Journal:  J Biol Chem       Date:  2015-01-06       Impact factor: 5.157

7.  Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.

Authors:  Andre Cassell; Maria L Freilino; Jessica Lee; Sharon Barr; Lin Wang; Mary C Panahandeh; Sufi M Thomas; Jennifer R Grandis
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

8.  Insulin-induced de novo lipid synthesis occurs mainly via mTOR-dependent regulation of proteostasis of SREBP-1c.

Authors:  Qingming Dong; Gipsy Majumdar; Robert N O'Meally; Robert N Cole; Marshall B Elam; Rajendra Raghow
Journal:  Mol Cell Biochem       Date:  2019-09-20       Impact factor: 3.396

9.  Mechanisms mediating the effects of alcohol and HIV anti-retroviral agents on mTORC1, mTORC2 and protein synthesis in myocytes.

Authors:  Ly Q Hong-Brown; Abid A Kazi; Charles H Lang
Journal:  World J Biol Chem       Date:  2012-06-26

10.  Targeting TOR dependence in cancer.

Authors:  Matthew R Janes; David A Fruman
Journal:  Oncotarget       Date:  2010-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.